Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences bidding to expand into large Chinese life sciences market

It comes as the Westlake Institute for Advanced Study (WIAS) has been named as Pressure's first Center of Excellence (CoE) in China.
Pressure BioSciences bidding to expand into large Chinese life sciences market
The company is bidding to expand into the large life sciences market in China

Pressure BioSciences Inc (OTCMKTS:PBIO) is bidding to take its sample preparation technology into the large life sciences market in China.

It comes as professor Tiannan Guo's laboratory at Westlake Institute for Advanced Study (WIAS) has been named as Pressure's first Center of Excellence (CoE) in China.

Guo and  Professor Ruedi Aebersold in Switzerland are co-developing PCT-SWATH, which is a novel method, which combines Pressure BioSciences' patented pressure cycling technology (PCT) platform with cutting-edge analytical capabilities of SCIEX's mass spectrometry SWATH method.

SCIEX, the life sciences tech firm, signed an exclusive co-marketing agreement with the firm in early 2016 to improve protein quantitation in complex samples.

"We are very pleased that Professor Guo will be leading the effort to establish and then direct our first CoE in China, " said Dr Nate Lawrence, vice president of marketing and sales.

"This Center is the first of its kind in Asia and joins our other Centers of Excellence in Europe and Australia as an important pillar in our global marketing and sales strategy.

"We believe Professor Guo's vast experience with the PCT platform, his expertise in proteomics and lipidomics, and his fluency in both Chinese and English will be invaluable in helping PBI quickly and successfully expand into the large life sciences market in China."

Guo added: "I believe strongly that PCT will have a significant impact in helping research scientists in China and around the world make new discoveries in multiple fields, including proteomics, genomics, lipidomics, and metabolomics."

Pressure BioSciences Inc shares were unchanged at US$3.94 at the time of writing.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use